Vertex Pharmaceuticals Incorporated (VRTX) Earnings Yield: 3.78%
Is Vertex Pharmaceuticals Incorporated’s earnings yield high or low?
Vertex Pharmaceuticals Incorporated's earnings yield of 3.78% is in line with its 5-year average of 3.65%, around the middle of its 5-year range (2.93%–5.60%).
The earnings yield for Vertex Pharmaceuticals Incorporated (VRTX) is 3.78% as of Tuesday, June 9, 2026. It is above its 12-month average by 11.35% (3.39%).
VRTX Earnings Yield Chart
VRTX Average Earnings Yield Chart
VRTX Current vs Average Earnings Yield Chart
VRTX Earnings Yield Metrics
EARNINGS YIELD
3.78%
EARNINGS YIELD AVG TTM
3.39%
EARNINGS YIELD AVG 3Y
3.39%
EARNINGS YIELD AVG 5Y
3.65%
EARNINGS YIELD AVG 10Y
2.91%
EARNINGS YIELD AVG 15Y
2.31%
EARNINGS YIELD AVG 20Y
2.31%
CURRENT VS TTM AVG
+11.35%
CURRENT VS 3Y AVG
+11.36%
CURRENT VS 5Y AVG
+3.61%
CURRENT VS 10Y AVG
+29.82%
CURRENT VS 15Y AVG
+63.61%
CURRENT VS 20Y AVG
+63.61%
VRTX Competitors' Earnings Yield
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated (VRTX) | — | 3.78% | 3.39% | 3.39% | 3.65% |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 6.30% | 5.69% | 6.70% | 5.30% |
| Medtronic plc (MDT) | $105.25B | 4.55% | 3.97% | 3.73% | 3.61% |
| CVS Health Corporation (CVS) | $123.84B | 2.34% | 2.93% | 5.90% | 5.70% |
| Danaher Corporation (DHR) | $133.37B | 2.74% | 2.43% | 2.72% | 3.03% |
| Elevance Health Inc. (ELV) | $92.17B | 5.54% | 7.31% | 6.27% | 5.78% |
| Pfizer Inc. (PFE) | $146.48B | 5.10% | 6.28% | 5.54% | 6.84% |
| Cigna Corporation (CI) | $78.04B | 7.99% | 7.37% | 5.81% | 6.73% |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 1.93% | 1.54% | 1.36% | 1.43% |
| Gilead Sciences, Inc. (GILD) | $155.82B | 5.85% | 4.73% | 3.68% | 4.37% |
Earnings Yield vs P/E Ratio
Earnings Yield
3.78%
EPS ÷ Price
P/E Ratio
26.4
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
- It expresses earnings relative to share price as a percentage
- It can be compared with FCF yield and dividend yield
- It can be compared with bond yields because both are percentages
- It is mathematically the inverse of the P/E ratio
Vertex Pharmaceuticals Incorporated Earnings Yield Formula & Definition
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Vertex Pharmaceuticals Incorporated Earnings Yield FAQ
- What is the earnings yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The earnings yield for VRTX stock is 3.78%.
- Is Vertex Pharmaceuticals Incorporated's earnings yield high or low?
- Vertex Pharmaceuticals Incorporated's earnings yield of 3.78% is in line with its 5-year average of 3.65%, around the middle of its 5-year range (2.93%–5.60%).
- What is the TTM average earnings yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The TTM average earnings yield for VRTX stock is 3.39%.
- What is the 3Y average earnings yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 3Y average earnings yield for VRTX stock is 3.39%.
- What is the 5Y average earnings yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 5Y average earnings yield for VRTX stock is 3.65%.
- What is the 10Y average earnings yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 10Y average earnings yield for VRTX stock is 2.91%.
- What is the 15Y average earnings yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 15Y average earnings yield for VRTX stock is 2.31%.
- What is the 20Y average earnings yield for Vertex Pharmaceuticals Incorporated (VRTX)?
- The 20Y average earnings yield for VRTX stock is 2.31%.
Vertex Pharmaceuticals Incorporated Earnings Yield History
| DATE | EARNINGS YIELD |
|---|---|
| 2026-06-09 | 3.78% |
| 2026-06-08 | 3.81% |
| 2026-06-05 | 3.77% |
| 2026-06-04 | 3.82% |
| 2026-06-03 | 3.94% |
| 2026-06-02 | 3.97% |
| 2026-06-01 | 3.85% |
| 2026-05-29 | 3.77% |
| 2026-05-28 | 3.76% |
| 2026-05-27 | 3.86% |
| 2026-05-26 | 3.87% |
| 2026-05-22 | 3.88% |
| 2026-05-21 | 3.89% |
| 2026-05-20 | 3.92% |
| 2026-05-19 | 3.88% |
| 2026-05-18 | 3.86% |
| 2026-05-15 | 3.86% |
| 2026-05-14 | 3.74% |
| 2026-05-13 | 3.72% |
| 2026-05-12 | 3.76% |
| 2026-05-11 | 3.87% |
| 2026-05-08 | 3.92% |
| 2026-05-07 | 3.97% |
| 2026-05-06 | 3.94% |
| 2026-05-05 | 3.97% |
| 2026-05-04 | 3.57% |
| 2026-05-01 | 3.62% |
| 2026-04-30 | 3.59% |
| 2026-04-29 | 3.62% |
| 2026-04-28 | 3.56% |
| 2026-04-27 | 3.60% |
| 2026-04-24 | 3.56% |
| 2026-04-23 | 3.52% |
| 2026-04-22 | 3.50% |
| 2026-04-21 | 3.51% |
| 2026-04-20 | 3.49% |
| 2026-04-17 | 3.47% |
| 2026-04-16 | 3.52% |
| 2026-04-15 | 3.47% |
| 2026-04-14 | 3.45% |
| 2026-04-13 | 3.48% |
| 2026-04-10 | 3.51% |
| 2026-04-09 | 3.43% |
| 2026-04-08 | 3.45% |
| 2026-04-07 | 3.55% |
| 2026-04-06 | 3.53% |
| 2026-04-02 | 3.49% |
| 2026-04-01 | 3.43% |
| 2026-03-31 | 3.43% |
| 2026-03-30 | 3.46% |
| 2026-03-27 | 3.54% |
| 2026-03-26 | 3.38% |
| 2026-03-25 | 3.37% |
| 2026-03-24 | 3.42% |
| 2026-03-23 | 3.40% |
| 2026-03-20 | 3.38% |
| 2026-03-19 | 3.35% |
| 2026-03-18 | 3.39% |
| 2026-03-17 | 3.31% |
| 2026-03-16 | 3.29% |
| 2026-03-13 | 3.27% |
| 2026-03-12 | 3.21% |
| 2026-03-11 | 3.11% |
| 2026-03-10 | 3.07% |
| 2026-03-09 | 3.33% |
| 2026-03-06 | 3.36% |
| 2026-03-05 | 3.33% |
| 2026-03-04 | 3.21% |
| 2026-03-03 | 3.23% |
| 2026-03-02 | 3.15% |
| 2026-02-27 | 3.09% |
| 2026-02-26 | 3.19% |
| 2026-02-25 | 3.17% |
| 2026-02-24 | 3.14% |
| 2026-02-23 | 3.19% |
| 2026-02-20 | 3.21% |
| 2026-02-19 | 3.27% |
| 2026-02-18 | 3.26% |
| 2026-02-17 | 3.21% |
| 2026-02-13 | 3.12% |
| 2026-02-12 | 3.05% |
| 2026-02-11 | 3.07% |
| 2026-02-10 | 3.06% |
| 2026-02-09 | 3.01% |
| 2026-02-06 | 2.97% |
| 2026-02-05 | 3.09% |
| 2026-02-04 | 3.01% |
| 2026-02-03 | 3.05% |
| 2026-02-02 | 3.00% |
| 2026-01-30 | 3.02% |
| 2026-01-29 | 2.98% |
| 2026-01-28 | 2.97% |
| 2026-01-27 | 2.99% |
| 2026-01-26 | 2.97% |
| 2026-01-23 | 3.03% |
| 2026-01-22 | 3.03% |
| 2026-01-21 | 3.08% |
| 2026-01-20 | 3.21% |
| 2026-01-16 | 3.21% |
| 2026-01-15 | 3.23% |
| 2026-01-14 | 3.15% |
| 2026-01-13 | 3.12% |
| 2026-01-12 | 3.08% |
| 2026-01-09 | 3.06% |
| 2026-01-08 | 3.02% |
| 2026-01-07 | 2.93% |
| 2026-01-06 | 3.03% |
| 2026-01-05 | 3.16% |
| 2026-01-02 | 3.14% |
| 2025-12-31 | 3.13% |
| 2025-12-30 | 3.13% |
| 2025-12-29 | 3.08% |
| 2025-12-26 | 3.06% |
| 2025-12-24 | 3.06% |
| 2025-12-23 | 3.09% |
| 2025-12-22 | 3.08% |
| 2025-12-19 | 3.11% |
| 2025-12-18 | 3.17% |
| 2025-12-17 | 3.15% |
| 2025-12-16 | 3.12% |
| 2025-12-15 | 3.11% |
| 2025-12-12 | 3.14% |
| 2025-12-11 | 3.18% |
| 2025-12-10 | 3.19% |
| 2025-12-09 | 3.24% |
| 2025-12-08 | 3.21% |
| 2025-12-05 | 3.11% |
| 2025-12-04 | 3.10% |
| 2025-12-03 | 3.06% |
| 2025-12-02 | 3.27% |
| 2025-12-01 | 3.33% |
| 2025-11-28 | 3.27% |
| 2025-11-26 | 3.28% |
| 2025-11-25 | 3.30% |
| 2025-11-24 | 3.34% |
| 2025-11-21 | 3.32% |
| 2025-11-20 | 3.36% |
| 2025-11-19 | 3.37% |
| 2025-11-18 | 3.26% |
| 2025-11-17 | 3.27% |
| 2025-11-14 | 3.24% |
| 2025-11-13 | 3.26% |
| 2025-11-12 | 3.27% |
| 2025-11-11 | 3.30% |
| 2025-11-10 | 3.37% |
| 2025-11-07 | 3.46% |
| 2025-11-06 | 3.41% |
| 2025-11-05 | 3.40% |
| 2025-11-04 | 3.36% |
| 2025-11-03 | 3.28% |
| 2025-10-31 | 3.29% |
| 2025-10-30 | 3.33% |
| 2025-10-29 | 3.35% |
| 2025-10-28 | 3.31% |
| 2025-10-27 | 3.33% |
| 2025-10-24 | 3.32% |
| 2025-10-23 | 3.31% |
| 2025-10-22 | 3.28% |
| 2025-10-21 | 3.28% |
| 2025-10-20 | 3.34% |
| 2025-10-17 | 3.36% |
| 2025-10-16 | 3.42% |
| 2025-10-15 | 3.43% |
| 2025-10-14 | 3.39% |
| 2025-10-13 | 3.43% |
| 2025-10-10 | 3.43% |
| 2025-10-09 | 3.37% |
| 2025-10-08 | 3.32% |
| 2025-10-07 | 3.41% |
| 2025-10-06 | 3.47% |
| 2025-10-03 | 3.47% |
| 2025-10-02 | 3.42% |
| 2025-10-01 | 3.46% |
| 2025-09-30 | 3.57% |
| 2025-09-29 | 3.54% |
| 2025-09-26 | 3.63% |
| 2025-09-25 | 3.66% |
| 2025-09-24 | 3.71% |
| 2025-09-23 | 3.68% |
| 2025-09-22 | 3.65% |
| 2025-09-19 | 3.65% |
| 2025-09-18 | 3.61% |
| 2025-09-17 | 3.61% |
| 2025-09-16 | 3.58% |
| 2025-09-15 | 3.56% |
| 2025-09-12 | 3.55% |
| 2025-09-11 | 3.52% |
| 2025-09-10 | 3.60% |
| 2025-09-09 | 3.53% |
| 2025-09-08 | 3.54% |
| 2025-09-05 | 3.53% |
| 2025-09-04 | 3.52% |
| 2025-09-03 | 3.53% |
| 2025-09-02 | 3.49% |
| 2025-08-29 | 3.58% |
| 2025-08-28 | 3.57% |
| 2025-08-27 | 3.60% |
| 2025-08-26 | 3.61% |
| 2025-08-25 | 3.60% |
| 2025-08-22 | 3.54% |
| 2025-08-21 | 3.52% |
| 2025-08-20 | 3.55% |
| 2025-08-19 | 3.58% |
| 2025-08-18 | 3.59% |
| 2025-08-15 | 3.56% |
| 2025-08-14 | 3.58% |
| 2025-08-13 | 3.53% |
| 2025-08-12 | 3.61% |
| 2025-08-11 | 3.74% |
| 2025-08-08 | 3.82% |
| 2025-08-07 | 3.72% |
| 2025-08-06 | 3.63% |
| 2025-08-05 | 3.73% |
| 2025-08-04 | 3.26% |
| 2025-08-01 | 3.33% |
| 2025-07-31 | 3.37% |
| 2025-07-30 | 3.28% |
| 2025-07-29 | 3.29% |
| 2025-07-28 | 3.34% |
| 2025-07-25 | 3.28% |
| 2025-07-24 | 3.26% |
| 2025-07-23 | 3.23% |
| 2025-07-22 | 3.28% |
| 2025-07-21 | 3.36% |
| 2025-07-18 | 3.35% |
| 2025-07-17 | 3.33% |
| 2025-07-16 | 3.28% |
| 2025-07-15 | 3.32% |
| 2025-07-14 | 3.26% |
| 2025-07-11 | 3.29% |
| 2025-07-10 | 3.21% |
| 2025-07-09 | 3.22% |
| 2025-07-08 | 3.30% |
| 2025-07-07 | 3.35% |
| 2025-07-03 | 3.35% |
| 2025-07-02 | 3.37% |
| 2025-07-01 | 3.41% |
| 2025-06-30 | 3.46% |
| 2025-06-27 | 3.49% |
| 2025-06-26 | 3.48% |
| 2025-06-25 | 3.46% |
| 2025-06-24 | 3.42% |
| 2025-06-23 | 3.47% |
| 2025-06-20 | 3.50% |
| 2025-06-18 | 3.44% |
| 2025-06-17 | 3.49% |
| 2025-06-16 | 3.42% |
| 2025-06-13 | 3.38% |
| 2025-06-12 | 3.35% |
| 2025-06-11 | 3.41% |
| 2025-06-10 | 3.41% |
| 2025-06-09 | 3.45% |
| 2025-06-06 | 3.42% |
| 2025-06-05 | 3.47% |
| 2025-06-04 | 3.46% |
| 2025-06-03 | 3.45% |
| 2025-06-02 | 3.46% |
| 2025-05-30 | 3.49% |
| 2025-05-29 | 3.45% |
| 2025-05-28 | 3.46% |
Showing the most recent 260 of 3,595 data points. The chart above shows the full history.
Related Metrics
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Reshma Kewalramani